about
Current approaches and challenges for monitoring treatment response in colon and rectal cancerMolecular imaging for cancer diagnosis and surgery.The 2D Hotelling filter - a quantitative noise-reducing principal-component filter for dynamic PET data, with applications in patient dose reductionDoes the availability of positron emission tomography modify diagnostic strategies for solitary pulmonary nodules? An observational study in France.The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT.Current status of positron emission tomography in oncology.Clinical applications of FDG-PET in oncology.Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapyLymphatic imaging: focus on imaging probes.A high-content screening platform with fluorescent chemical probes for the discovery of first-in-class therapeutics.Clinical significance of SUVmax in (18)F-FDG PET/CT scan for detecting nodal metastases in patients with oral squamous cell carcinomaThe value of delayed (18)F FDG-PET imaging in diagnosis of solitary pulmonary nodules: A preliminary study on 28 patientsA prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomyUncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.Application of positron emission tomography imaging to cancer screening.Study of the performance of a novel 1 mm resolution dual-panel PET camera design dedicated to breast cancer imaging using Monte Carlo simulation.Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectorsIntraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticleEfficacy of FDG-PET for defining gross tumor volume of head and neck cancer.[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.Image-guided surgery using multimodality strategy and molecular probes.Exploiting the mechanism of cellular glucose uptake to develop an image-based high-throughput screening system in living cells.Synthesis and biodistribution of a new (99m) Tc-oxo complex with deoxyglucose dithiocarbamate for tumor imaging.Tc-99m glucoheptonate is poor man's fluorodeoxyglucose.Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging bFalse-positive (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with metallic implants following chondrosarcoma resection.Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma.Metformin and cancer: Technical and clinical implications for FDG-PET imaging.Comparison of PET/CT with conventional imaging modalities (USG, CECT) in evaluation of N0 neck in head and neck squamous cell carcinoma.Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins.A statistical clustering approach to visualizing the relationship between early and delayed images in whole-body FDG-PET.Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer.[Basic principles of 18F-fluorodeoxyglucose positron emission tomography]Synthesis, quality control, and bio-evaluation of 99m Tc-cyclophosphamide.EGFR-Targeted Magnetic Nanovectors Recognize, in Vivo, Head and Neck Squamous Cells Carcinoma-Derived Tumors.Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among 11C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC-Preliminary Results.Lesion detectability and clinical effectiveness of dual-head coincidence gamma camera imaging in comparison with dedicated PET systems in tumour patients.Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system.The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management.
P2860
Q27010257-E1A41299-1C08-49F4-A4F9-7D1516E9539FQ27687291-1016EC11-41D3-4AD4-A6AE-E1D44A694B08Q30614597-04436E2F-A370-4FDF-ABB8-28927DF31877Q33442125-03CEDA88-60FE-48EE-A39E-6F24B1AA8B46Q33704152-656E669A-1F87-493F-AE4C-E7F7FE2E4181Q34322405-DE7D445B-A995-4339-BA41-19CD670FA0CBQ35036165-D3ADCF15-2308-4DBD-AA63-07FA42A9E831Q35090262-CEFAD9A9-4198-464E-9478-6A8835683793Q35475925-2FAA7D8D-B40B-4959-B7D6-602F598309E4Q36013948-2B3C9055-2B37-4375-8168-773FF5DE0F2DQ36308023-18E4ACCB-6915-4BBD-9EAA-B7842A5FD673Q36394204-E968FE3A-BCC1-48F0-83CF-8C5CDB43E18DQ36430749-183BA319-6BC5-43C0-82C5-451623F02B8BQ36617954-B1F4D579-8B6A-4CEF-9A22-C8768E5C4645Q36621633-D112F29E-15B5-43FA-A0ED-6877354C723BQ36966166-E461C0D0-018B-4E20-97FB-787BCC857C50Q36988753-4DFB9C5D-CEA2-4A1C-BD0E-B5999BA63D98Q36994123-EA06077B-0D76-4D40-A5A3-9987619C8E0AQ37006913-0932B5C3-F1BE-4DCF-8B88-FC312B6C4911Q37085677-F65F10D0-6765-457F-B7E1-DA4D6DFD90D4Q38520183-E18D4502-F916-479E-BB92-12596630D580Q39158561-0A51D2B7-976A-4982-81B2-C80DC355B1C5Q39434037-BEEA665A-08A0-4D03-9E14-56C725FFA4C9Q39488915-140B795D-3A23-4E6C-80A8-9932C65B81C2Q39557749-72CB2B4F-E52C-4BB7-A4B0-AC8A4A42914AQ40487781-511C199D-B3B8-4A33-82E5-D5850CFB9E11Q40873152-293E0C13-4C37-4CAF-83F8-AF8C0B61D54EQ41136911-3505289A-30E1-480C-98A7-B8D8E9DDF556Q42020288-3B8787B9-4F2F-4DCC-BC6B-0F4E52504F40Q42484107-0FB4AD31-7946-4673-91A6-6918DD13AB89Q42915774-D4A56F4E-ACEC-4663-AB61-EB945E3E19F8Q44096081-EF44A233-ED88-4D0C-8A7C-6A168DC76125Q44266124-34351440-1D33-4D2C-9290-279EB43DA6FCQ47698254-B94641C7-507B-4C0D-8F8C-10A677493C5DQ47772716-E7BC11C1-7ABA-42F9-BD02-41AED667F3EDQ48270232-AA59638D-01DC-4742-A407-3A673BC3E683Q50935918-7EF11927-AAA7-4509-85B3-2DA598485AC7Q52831385-DEBDF85B-731B-4101-B78C-2A3388DE14F2Q53215589-87EF0E31-AC41-462D-86C6-FC8C84D8994A
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
PET and [18F]-FDG in oncology: a clinical update.
@en
type
label
PET and [18F]-FDG in oncology: a clinical update.
@en
prefLabel
PET and [18F]-FDG in oncology: a clinical update.
@en
P2093
P1476
PET and [18F]-FDG in oncology: a clinical update.
@en
P2093
P304
P356
10.1016/0969-8051(96)00074-1
P577
1996-08-01T00:00:00Z